- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oryzon Genomics SA (ORY)
Oryzon Genomics SA stock price live, this page displays BME ORY stock exchange data. View the ORY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Oryzon Genomics SA real time stock price chart below.
What Is the Oryzon Genomics SA Stock Price Today?
The Oryzon Genomics SA stock price today is 2.828.
What Is the Stock Symbol for Oryzon Genomics SA?
The stock symbol for Oryzon Genomics SA is "ORY."
What Stock Exchange Does Oryzon Genomics SA Trade On?
Oryzon Genomics SA is listed and trades on the Madrid stock exchange.
Is Oryzon Genomics SA a Good Stock to Buy?
Determining whether Oryzon Genomics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ORY quote. (ISIN: ES0167733015)
What Is the Oryzon Genomics SA Stock Price Today?
The Oryzon Genomics SA stock price today is 2.828.
What Is the Stock Symbol for Oryzon Genomics SA?
The stock symbol for Oryzon Genomics SA is "ORY."
What Stock Exchange Does Oryzon Genomics SA Trade On?
Oryzon Genomics SA is listed and trades on the Madrid stock exchange.
Is Oryzon Genomics SA a Good Stock to Buy?
Determining whether Oryzon Genomics SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ORY quote. (ISIN: ES0167733015)
2.828
0.000(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.818
2.862
52 wk Range
2.555
4.020
ORY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8182.862
52 wk Range
2.5554.020
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ORY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
7.067
Upside
+149.88%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Compare ORY to Peers and Sector
Metrics to compare | ORY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −84.1x | 12.4x | −0.4x | |
PEG Ratio | −2.15 | 0.05 | 0.00 | |
Price/Book | 1.9x | 1.8x | 2.6x | |
Price / LTM Sales | 20.0x | 3.0x | 3.2x | |
Upside (Analyst Target) | 83.9% | 363.6% | 46.7% | |
Fair Value Upside | Unlock | −8.8% | 7.6% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.067
(+149.88% Upside)
Earnings
Latest Release
Feb 27, 2026
EPS / Forecast
-0.02 / -0.03
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Oryzon Genomics (ORY) Stock Price Today?
The Oryzon Genomics stock price today is 2.828 EUR.
What Stock Exchange Does Oryzon Genomics Trade On?
Oryzon Genomics is listed and trades on the Madrid Stock Exchange.
What Is the Stock Symbol for Oryzon Genomics?
The stock symbol for Oryzon Genomics is "ORY."
What Is the Oryzon Genomics Market Cap?
As of today, Oryzon Genomics market cap is 219.830M EUR.
What Is Oryzon Genomics's Earnings Per Share (TTM)?
The Oryzon Genomics EPS (TTM) is -0.034.
When Is the Next Oryzon Genomics Earnings Date?
Oryzon Genomics will release its next earnings report on May 18, 2026.
From a Technical Analysis Perspective, Is ORY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Oryzon Genomics Stock Split?
Oryzon Genomics has split 0 times.
How Many Employees Does Oryzon Genomics Have?
Oryzon Genomics has 46 employees.
What is the current trading status of Oryzon Genomics (ORY)?
As of Apr 24, 2026, Oryzon Genomics (ORY) is trading at a price of 2.828 EUR, with a previous close of 2.828 EUR. The stock has fluctuated within a day range of 2.818 EUR to 2.862 EUR, while its 52-week range spans from 2.555 EUR to 4.020 EUR.
What Is Oryzon Genomics (ORY) Price Target According to Analysts?
The average 12-month price target for Oryzon Genomics is 7.067 EUR, with a high estimate of 12 EUR and a low estimate of 4 EUR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +149.88% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.